Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00413959 · ClinicalTrials.gov registry record · Phase 2
VELCADE,Rituximab,Cyclophosphamide and Decadron
A Phase 2 study, sponsored by Oncology Specialists, S.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00413959 is a Phase 2 study that was terminated before completion, run by Oncology Specialists, S.C.. The registered enrollment target is 12 participants.
The verdict
NCT00413959, a Phase 2 study, was terminated before completion, sponsored by Oncology Specialists, S.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Rituximab
- DRUG Decadron
- DRUG VELCADE®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-08 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00413959
The ClinicalTrials.gov registry entry for NCT00413959 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00413959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00413959 about?
NCT00413959 is a clinical study titled "VELCADE,Rituximab,Cyclophosphamide and Decadron". Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
What is the current status of trial NCT00413959?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00413959?
The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Decadron (DRUG), VELCADE® (DRUG).
Who is sponsoring clinical trial NCT00413959?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.